Team:RAMNOTIREN CALGARY
From 2014hs.igem.org
(33 intermediate revisions not shown) | |||
Line 22: | Line 22: | ||
#box1 { | #box1 { | ||
- | width: | + | width: 990px; |
margin-top: 8px; | margin-top: 8px; | ||
background: #E6E6E6; /*threedface*/ | background: #E6E6E6; /*threedface*/ | ||
Line 29: | Line 29: | ||
margin-bottom: 13px; | margin-bottom: 13px; | ||
position: relative; | position: relative; | ||
- | left: - | + | left: -60px; |
} | } | ||
Line 36: | Line 36: | ||
padding: 20px 0px 0px 10px; | padding: 20px 0px 0px 10px; | ||
font-family: arial, verdana, "lucida sans"; | font-family: arial, verdana, "lucida sans"; | ||
- | text- | + | text-align: center; |
+ | |||
} | } | ||
Line 113: | Line 114: | ||
.visualClear { | .visualClear { | ||
display: none; | display: none; | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
} | } | ||
Line 126: | Line 120: | ||
} | } | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
#search-controls { | #search-controls { | ||
Line 178: | Line 147: | ||
display: none; | display: none; | ||
} | } | ||
+ | |||
+ | #vidbutt{ | ||
+ | position: relative; | ||
+ | top:0px; | ||
+ | left:-60px; | ||
+ | background-color: #e6e6e6; | ||
+ | padding: 0px 15px 0px 15px; | ||
+ | border-radius: 5px; | ||
+ | } | ||
+ | |||
+ | #notebutt{ | ||
+ | position: relative; | ||
+ | top: -300px; | ||
+ | left: 286px; | ||
+ | background-color: #e6e6e6; | ||
+ | padding: 0px 15px 20px 15px; | ||
+ | border-radius: 5px; | ||
+ | } | ||
+ | |||
+ | |||
#tweets{ | #tweets{ | ||
position: relative; | position: relative; | ||
- | + | top:-834px; | |
- | + | left:642px; | |
- | width: | + | width: 280px; |
} | } | ||
#countdown{ | #countdown{ | ||
position: relative; | position: relative; | ||
- | + | top: -815px; | |
- | + | left:642px; | |
- | + | ||
} | } | ||
+ | |||
+ | |||
#sponsorsbox{ | #sponsorsbox{ | ||
clear: both; | clear: both; | ||
position: relative; | position: relative; | ||
+ | top: -600px; | ||
left: -70px; | left: -70px; | ||
width: 1005px; | width: 1005px; | ||
margin: 4px 0px; | margin: 4px 0px; | ||
- | background: # | + | background: #EEEEEE; |
+ | border-radius: 3px; | ||
} | } | ||
#sponsorsbox h4{ | #sponsorsbox h4{ | ||
Line 221: | Line 213: | ||
margin-left: auto; | margin-left: auto; | ||
} | } | ||
+ | |||
+ | #exp1{ | ||
+ | position: relative; | ||
+ | top:-310px; | ||
+ | left:-58px; | ||
+ | background-color: #e6e6e6; | ||
+ | padding: 10px 10px 10px 10px; | ||
+ | width: 308px; | ||
+ | } | ||
+ | |||
+ | #exp2{ | ||
+ | position: relative; | ||
+ | top:-405px; | ||
+ | left: 288px; | ||
+ | background-color: #e6e6e6; | ||
+ | padding: 10px 10px 10px 10px; | ||
+ | width: 308px; | ||
+ | } | ||
</style> | </style> | ||
Line 315: | Line 325: | ||
<ul> | <ul> | ||
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members">Members</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members">Members</a></li> | ||
- | <li><a href="https://igem.org/Team.cgi" target="_blank">Official Profile</a></li> | + | <li><a href="https://igem.org/Team.cgi?id=1295" target="_blank">Official Profile</a></li> |
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li> | ||
</ul> | </ul> | ||
</li> | </li> | ||
- | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content" id="projectlink"> | + | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content" id="projectlink">Content</a> |
<ul> | <ul> | ||
- | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content"> | + | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content">Overview</a></li> |
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li> | ||
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Safety">Safety</a></li> | <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Safety">Safety</a></li> | ||
Line 346: | Line 356: | ||
</div> | </div> | ||
+ | |||
+ | <div id="button1"> | ||
+ | <a href="http://www.youtube.com/watch?v=C_5Z31mUmtc"><img id="vidbutt" src="https://static.igem.org/mediawiki/2014hs/6/67/VideoButton.png" width="300px" height="300px"></a> | ||
+ | </div> | ||
+ | |||
+ | <div id="button2"> | ||
+ | <a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Notebook"><img id="notebutt" src="https://static.igem.org/mediawiki/2014hs/9/95/Notebook.png" width="300px" height="300px"></a> | ||
+ | |||
+ | <div id="exp1"> | ||
+ | <p>Click here to see the introductory video we used to familiarize ouselves with what we would be researching. </p> | ||
+ | </div> | ||
+ | |||
+ | <div id="exp2"> | ||
+ | <p>Here is a record of our. We also want to thank everybody who helped us along the way!</p> | ||
+ | </div> | ||
+ | |||
<div id="tweets"> | <div id="tweets"> | ||
Line 353: | Line 379: | ||
<div id="countdown"> | <div id="countdown"> | ||
- | + | <iframe src="http://free.timeanddate.com/countdown/i478w11x/n43/cf111/cm0/cu4/ct3/cs1/ca2/co1/cr2/ss0/cac000/cpc000/pc9542aa/tc9542aa/fs90/szw256/szh108/tatCountdown%20to%20iGEM%20Jamboree/tac000/tptTime%20since%20Event%20started%20in/tpc000/iso2014-06-26T00:00:00/bo2" frameborder="0" width="258" height="110"></iframe> | |
+ | |||
</div> | </div> | ||
Latest revision as of 04:02, 21 June 2014
Choking Cancer
Every year approximately eight million people die of cancer, and an additional fourteen million are diagnosed with the disease. The World Heath Organization predicts that without immediate action these numbers will increase by eighty percent by the year 2030.
Cancer needs an abundant source of oxygenated blood to grow. To achieve this cancer cells release angiogenic factors that promote vascular growth. Without these factors, cancer is unable to survive. Consequently, current treatments focus on targeting/inhibiting the angiogenic factors released by cancer cells. Targeted therapy has also been a successful treatment option.
Our project aims to combine these two therapeutic approaches to create a synthetic biological machine that seeks out cancer cells and inhibits angiogenesis. We plan to design a bacterium that in the presence of cancer cells secretes an anti-angiogenic factor. This will inhibit the growth of the capillary system that is crucial for cancer cell survival.